Bristol-Myers Squibb Company
Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides

Last updated:

Abstract:

Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

Status:
Application
Type:

Utility

Filling date:

20 Dec 2021

Issue date:

16 Jun 2022